- Home
- NRIX vs EOS Comparison
NRIX vs EOS Comparison
Compare NRIX & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- EOS
- Stock Information
- Founded
- NRIX 2009
- EOS 2005
- Country
- NRIX United States
- EOS United States
- Employees
- NRIX N/A
- EOS N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- EOS Trusts Except Educational Religious and Charitable
- Sector
- NRIX Health Care
- EOS Finance
- Exchange
- NRIX Nasdaq
- EOS Nasdaq
- Market Cap
- NRIX 1.1B
- EOS N/A
- IPO Year
- NRIX 2020
- EOS N/A
- Fundamental
- Price
- NRIX $11.38
- EOS $21.36
- Analyst Decision
- NRIX Strong Buy
- EOS
- Analyst Count
- NRIX 17
- EOS 0
- Target Price
- NRIX $30.82
- EOS N/A
- AVG Volume (30 Days)
- NRIX 980.6K
- EOS 84.1K
- Earning Date
- NRIX 04-14-2025
- EOS 01-01-0001
- Dividend Yield
- NRIX N/A
- EOS 6.80%
- EPS Growth
- NRIX N/A
- EOS N/A
- EPS
- NRIX N/A
- EOS N/A
- Revenue
- NRIX $54,549,000.00
- EOS N/A
- Revenue This Year
- NRIX N/A
- EOS N/A
- Revenue Next Year
- NRIX $3.20
- EOS N/A
- P/E Ratio
- NRIX N/A
- EOS N/A
- Revenue Growth
- NRIX N/A
- EOS N/A
- 52 Week Low
- NRIX $10.21
- EOS $15.62
- 52 Week High
- NRIX $29.56
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- NRIX 32.85
- EOS 35.56
- Support Level
- NRIX $12.20
- EOS $20.60
- Resistance Level
- NRIX $13.10
- EOS $22.57
- Average True Range (ATR)
- NRIX 0.79
- EOS 0.41
- MACD
- NRIX -0.09
- EOS -0.03
- Stochastic Oscillator
- NRIX 26.71
- EOS 38.58
Stock Price Comparison Chart: NRIX vs EOS
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.